Additional file 1 of Diagnostic potential of a circulating miRNA model associated with therapeutic effect in heart failure

Additional file 1: Table S1. Characteristics of HF patients in the discovery phase (n=40). Table S2. Characteristics of HF patients in the training phase (n=30) and validation phase (n=50). Table S3. Home made circulating miRNA panel which was used for the miRNA screening analysis in the discovery phase. Table S4. The features of 11 overlapped target genes of miR-30a-5p in Heart Failure (ICM or DCM). Table S5. The features of 9 overlapped target genes of miR-654-5p between Heart Failure (ICM or DCM). Figure S1. Expression patterns of circulating miR-100, miR-320a, miR-433 and miR-499b-3p in each patient in the discovery phase with paired plasma samples collected at times of check-in and check-out. The p-values showed significant change of the four miRNAs (p < 0.05). Figure S2. Expression patterns and change trends of the rest of 83 circulating miRNAs in all patients in the discovery phase. The p-values of these miRNAs did not show significant change. Figure S3. Correlation analysis between miR-30a-5p, miR-654-5p and NT-proBNP in the 40 HF patients enrolled in the discovery phase before and after treatment. Figure S4. Correlation analysis between the differential miRNA expression change and the NT-proBNP reduction by comparing 5 patients with ~80% NT-proBNP reduction and 5 patients with ~40% NT-proBNP reduction upon medical therapy (n=5, *p < 0.05).